Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab + pomalidomide + dexamethasone consolidation after autologous transplant in newly diagnosed multiple myeloma
jRCT2011230049Phase 2Active, not recruiting
- Sponsor
- Sanofi
- Start
- Jan 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of isatuximab, pomalidomide and dexamethasone in multiple myeloma (MM), sponsored by Sanofi. Primary endpoint: Complete response rate after consolidation therapy. Started Jan 2024; status: active, not recruiting.
02
Drugs
isatuximabpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2011230049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011230049.